New pill shows promise for rare blood disorder PNH in early trial
Disease control
Ongoing
This Phase 2 trial tests an experimental oral drug called NTQ5082 for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder that causes red blood cells to break down. The study involves 24 adults who have not previously received complement inhibitor therapy…
Phase: PHASE2 • Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical • Aim: Disease control
Last updated May 07, 2026 18:41 UTC